Filana Therapeutics (FLNA) Accumulated Depreciation (2011 - 2026)

Filana Therapeutics has reported Accumulated Depreciation for 9 years, with the latest figure at $4.6 million in Q2 2026.

• On a quarterly basis, Accumulated Depreciation rose 25.68% year-over-year to $4.6 million in Q2 2026; TTM through Jun 2026 was $4.6 million, a 25.68% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 27.9% from the prior year.
• Accumulated Depreciation was $4.6 million for Q2 2026 at Filana Therapeutics, up from $4.4 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $4.6 million in Q2 2026, with the low at $574000.0 in Q1 2022.
• Average Accumulated Depreciation over 5 years is $2.6 million, with a median of $2.7 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Accumulated Depreciation surged 328.11% in 2022, then grew 25.68% in 2026.
• Over 5 years, Accumulated Depreciation stood at $1.2 million in 2022, then jumped by 90.33% to $2.3 million in 2023, then jumped by 41.68% to $3.2 million in 2024, then rose by 27.9% to $4.1 million in 2025, then grew by 11.26% to $4.6 million in 2026.
• The last three Accumulated Depreciation figures came in at $4.6 million (Q2 2026), $4.4 million (Q1 2026), and $4.1 million (Q4 2025), per Business Quant data.